U.S. Markets closed

Verastem, Inc. (VSTM)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
3.53+0.02 (+0.57%)
At close: 4:00PM EDT
People also watch
STMLOMEDCERURGLSINFI
  • KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • Mid year (june thru july) is almost done right? I saw many articles that said the news would be in june 2017.

    whats the deal?
  • Hiring an experienced CFO with audit experience indicates a high level of confidence that duvelisib will be generating significant revenue, especially since the company already has a financial person.
  • can we see green today please. I'm tired of looking at red
  • Exclusive: Verastem CEO Talks Duvelisib, Pipeline Data, And Further Upside For The Stock

    https://www.benzinga.com/general/biotech/17/07/9784256/exclusive-verastem-ceo-talks-duvelisib-pipeline-data-and-further-upsid

  • Penny, Nickle, Maybe a Dime ??? Oh Yeah We Had To Give New CFO 300,000 Shares. Look Out She's From The Clinton Foundation. This Stock Maybe Worthless By The End Of The Year, If The Clinton Name Is Anywhere In A Portfolio.???
  • I bought at $1.25 All The Way To The Bank!!!! Hold On Baby It's Long And Hard.
  • BMY sharks circling INFI
  • Yes...let's squeeze all of these pesky shorts out so that we can have some stability. The price is climbing back up nicely.....
  • Verastem (VSTM) which has made a huge move recently is finally getting some positive acknowledgement in the analyst community. After having Hold ratings reiterated at Jefferies and Cantor Fitzgerald over the past month, Oppenheimer today takes a more optimistic view on the company with a Buy rating and $6 price target. Positive trial results have really bolstered the shares so far in July and the company named a new CFO this week as well. The shares have also now doubled since we did a Spotlight feature on this small concern in June.
  • Did anyone else see $VSTM report from http://jcharlesassets.com/opiant-pharmaceuticals/?s=VSTM ? It had some interesting information. Investing day trading. "hhse"

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • Guess the fundamental level is about 4. The run to 4.54 was the shorts getting squeezed, painfully. This is a tough one to short. With volume 10x a month or two ago it is no longer day traders calling the shots. It's bigger players with good sources of info. Low valuation with a potential Phase 3 to read out probably in August. Also big players (Merck and Pfizer) probably watching the Ph 1 combo trials with defactinib.
  • The🌱most🌱beautiful🌱thing🌱in🌱the🌱world🌱is,🌱of🌱course,🌱the🌱world🌱itself. http://dataunion.tistory.com/3611

    Verastem Inc NASDAQ : VSTM Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.1 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • can anyone please give give me a prediction. whether it be for short term hold or long term?
  • Going to 4 today feeling
  • Excellent job short boys! Get ready for some more massive losses...
  • close in the green today?
  • Good luck with 5's this week haha... start of a multi day rundown here with nothing getting released... short all the way back to reality for me here.
  • if VSTM DROPS BELOW $3.45 THE NEW CFO WONT GET PAID MUCH, SHE SEEMED TO BE VERY CAPABLE WOMEN WITH A LOT OF EXPERIENCE. THIS IS MY FLOOR PRICE FOR NOW. HOW HIGH CAN IT GO, I DONT KNOW, BUT RECENT ACTIONS WERE AMAZING....

    Inducement Equity Awards
    In connection with the hiring of Ms. Feder, effective July 10, 2017, Verastem approved a grant to Ms. Feder of a stock option to purchase 370,000 shares of Verastem's common stock. The option was granted pursuant to the NASDAQ inducement grant exception as a component of Ms. Feder’s employment compensation and was granted as an inducement material to her acceptance of employment with Verastem in accordance with NASDAQ Listing Rule 5635(c)(4). The option will have an exercise price equal to $3.45, the closing price of Verastem's common stock on July 10, 2017.

    https://seekingalpha.com/pr/16883927-verastem-names-julie-b-feder-chief-financial-officer

    Verastem Names Julie B. Feder as Chief Financial Officer
    seekingalpha.com
  • I want to see $5 next week!